Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops drugs that target genetically determined dependencies within the chromatin regulatory system. The company is headquartered in Cambridge, Massachusetts.
| Revenue (TTM) | $36.74M |
| Gross Profit (TTM) | $-42.09M |
| EBITDA | $-66.35M |
| Operating Margin | -54.80% |
| Return on Equity | -470.40% |
| Return on Assets | -19.90% |
| Revenue/Share (TTM) | $0.55 |
| Book Value | $-1.38 |
| Price-to-Book | 2005.35 |
| Price-to-Sales (TTM) | 2.99 |
| EV/Revenue | 2.867 |
| EV/EBITDA | -1.21 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 112.70% |
| Shares Outstanding | $59.38M |
| Float | $25.58M |
| % Insiders | 14.13% |
| % Institutions | 81.68% |
Volatility is currently contracting
NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Foghorn Therapeutics Inc. ("Foghorn" or the "Company") (NASDAQ: FHTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Foghorn Therapeutics Inc. (“Foghorn” or the “Company”) (NASDAQ: FHTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
LOS ANGELES--(BUSINESS WIRE)---- $FHTX--FHTX Investors with $100,000 in Losses Have Opportunity to Join Foghorn Therapeutics Inc. Fraud Investigation with SBS Law.
NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Foghorn Therapeutics Inc. ("Foghorn" or the "Company") (NASDAQ: FHTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Foghorn Therapeutics Inc. (“Foghorn” or the “Company”) (NASDAQ: FHTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Foghorn and Lilly will not advance FHD-909; The Collaboration also will not advance the Selective SMARCA2 degrader program Company to focus resources on wholly owned pipeline, including a Selective EP300 degrader, a novel, oral immunology and inflammation program, a Selective CBP degrader and induced proximity platform Pipeline prioritization and organizational changes expected to extend cash runway into the second half of 2029, including an approximately 40% workforce reduction WATERTOWN, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a biotechnology company pioneering a new class of medicines that treat serious diseases, today announced that, following a review of clinical data from the Phase 1 dose escalation trial of FHD-909 (LY4050784), Foghorn and Lilly have decided not to advance the program into the clinical development expansion phase.
The consensus price target hints at a 67% upside potential for Foghorn Therapeutics (FHTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Does Foghorn Therapeutics Inc. (FHTX) have what it takes to be a top stock pick for momentum investors? Let's find out.
The mean of analysts' price targets for Foghorn Therapeutics (FHTX) points to an 88.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.28 per share a year ago.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on FHTX and any ticker you trade — then tracks every position and per-strategy win rate.
